Omalizumab may decrease the thickness of the reticular basement membrane and fibronectin deposit in the bronchial mucosa of severe allergic asthmatics

References

• Samitas K, Delimpoura V, Zervas E, Gaga M. Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives. Eur Respir Rev 2015;24:594–601. doi:10.1183/16000617.00001715.
   PubMed Web of Science ®Google Scholar
• Bazan-Socha S, Bukiej A, Marcinkiewicz C, Musial J. Integrins in pulmonary inflammatory diseases. Curr Pharm Des 2005;11:893–901.
   PubMed Web of Science ®Google Scholar
• Fahy JV. Remodeling of the airway epithelium in asthma. Am J Respir Crit Care Med 2001;164:S46–S51. doi:10.1164/ajrccm.164.supplement_2.2106066.
   PubMed Web of Science ®Google Scholar
• Chetta A, Foresi A, Del Donno M, Bertorelli G, Pesci A, Olivieri D. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 1997;111:852–857.
   PubMed Web of Science ®Google Scholar
• Lazaar AL, Panettieri RA. Jr., Airway smooth muscle: a modulator of airway remodeling in asthma. J Allergy Clin Immunol 2005;116:488–495. doi:10.1016/j.jaci.2005.06.030.
   PubMed Web of Science ®Google Scholar
• Benayoun L, Druilhe A, Dombret M-C, Aubier M, Pretolani M. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003;167:1360–1368. doi:10.1164/rccm.200209-1030OC.
   PubMed Web of Science ®Google Scholar
• Takhar P, Corrigan CJ, Smurthwaite L, O'Connor BJ, Durham SR, Lee TH, Gould HJ, et al. Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol 2007;119:213–218. doi:10.1016/j.jaci.2006.09.045.
   PubMed Web of Science ®Google Scholar
• Campbell AM, Vachier I, Chanez P, Vignola AM, Lebel B, Kochan J, Godard P, et al. Expression of the high-affinity receptor for IgE on bronchial epithelial cells of asthmatics. Am J Respir Cell Mol Biol 1998;19:92–97. doi:10.1165/ajrcmb.19.1.2648.
   PubMed Web of Science ®Google Scholar
• Gounni AS, Wellemans V, Yang J, Bellesort F, Kassiri K, Gangloff S, Guenounou M, et al. Human airway smooth muscle cells express the high affinity receptor for IgE (Fc epsilon RI): a critical role of Fc epsilon RI in human airway smooth muscle cell function. J Immunol 2005;175:2613–2621.
   PubMed Web of Science ®Google Scholar
• Roth M, Zhong J, Zumkeller C, S'ng CT, Goulet S, Tamm M. The role of IgE receptors in IgE-dependent airway smooth muscle cell remodeling. PLoS One 2013;8:e56015.
   PubMed Web of Science ®Google Scholar
• Roth M, Zhao F, Zhong J, Lardinois D, Tamm M. Serum IgE induced airway smooth muscle cell remodeling is independent of allergens and is prevented by omalizumab. PLoS One 2015;10:e0136549.
   PubMed Web of Science ®Google Scholar
• Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 2004;114:527–530. doi:10.1016/j.jaci.2004.06.032.
   PubMed Web of Science ®Google Scholar
• Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003;112:1147–1154. doi:10.1016/j.jaci.2003.10.003.
   PubMed Web of Science ®Google Scholar
• Oliver JM, Tarleton CA, Gilmartin L, Archibeque T, Qualls CR, Diehl L, Wilson BS, et al. Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy. Int Arch Allergy Immunol 2010;151:275–284. doi:10.1159/000250436.
   PubMed Web of Science ®Google Scholar
• Chand HS, Schuyler M, Joste N, Hensler C, Tesfaigzi Y, Masten B, Schrader R, et al. Anti-IgE therapy results in decreased myeloid dendritic cells in asthmatic airways. J Allergy Clin Immunol 2010;125:1157–1158.e5. doi:10.1016/j.jaci.2010.01.020.
   PubMed Web of Science ®Google Scholar
• Djukanović R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004;170:583–593. 15doi:10.1164/rccm.200312-1651OC.
   PubMed Web of Science ®Google Scholar
• Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005;35:408–416. doi:10.1111/j.1365-2222.2005.02191.x.
   PubMed Web of Science ®Google Scholar
• ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001;164:744–748. doi:10.1164/ajrccm.164.5.2011026.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Medical Section of the American Lung Association. Guidelines for fiberoptic bronchoscopy in adults. Am Rev Respir Dis 1987; 136:1066.
   PubMed Web of Science ®Google Scholar
• Zastrzezynska W, Przybyszowski M, Gawlewicz-Mroczka A. Efficacy of omalizumab in severe allergic asthma - preliminary experience from the University Hospital in Cracow, Poland. Przegląd Lekarski 2018;6:270–274.
   Google Scholar
• Reddel HK, Taylor DR, Bateman ED, Boulet L-P, Boushey HA, Busse WW, Casale TB, on behalf of the American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations, et al. An Official American Thoracic Society/European Respiratory Society Statement: Asthma control and exacerbations standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59–99. doi:10.1164/rccm.200801-060ST.
   PubMed Web of Science ®Google Scholar
• Zastrzeżyńska W, Gawlewicz-Mroczka A, Soja J, Sładek K, Musiał J, Bazan-Socha S. Omalizumab is effective and available for treatment of patients with severe allergic asthma in Poland. Pol Arch Intern Med 2017;127:715–717.
   PubMedGoogle Scholar
• Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration 2012;83:520–528. doi:10.1159/000334701.
   PubMed Web of Science ®Google Scholar
• Riccio AM, Dal Negro RW, Micheletto C, De Ferrari L, Folli C, Chiappori A, Canonica GW, et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int J Immunopathol Pharmacol 2012;25:475–484. doi:10.1177/039463201202500217.
   PubMed Web of Science ®Google Scholar
• Mauri P, Riccio AM, Rossi R, Di Silvestre D, Benazzi L, De Ferrari L, Negro RWD, et al. Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. Immunol Lett 2014;162:2–10. doi:10.1016/j.imlet.2014.08.010.
   PubMed Web of Science ®Google Scholar
• Riccio AM, Mauri P, De Ferrari L, Rossi R, Di Silvestre D, Benazzi L, Chiappori A, et al. Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months. Clin Transl Allergy 2017;7:6. doi:10.1186/s13601-017-0143-1.
   PubMed Web of Science ®Google Scholar
• James AL, Bai TR, Mauad T, Abramson MJ, Dolhnikoff M, McKay KO, Maxwell PS, et al. Airway smooth muscle thickness in asthma is related to severity but not duration of asthma. Eur Respir J 2009;34:1040–1045.
   PubMed Web of Science ®Google Scholar
• Hocking DC. Fibronectin matrix deposition and cell contractility: implications for airway remodeling in asthma. Chest 2002;122:275S–278S.
   PubMed Web of Science ®Google Scholar
• Burgess JK. The role of the extracellular matrix and specific growth factors in the regulation of inflammation and remodelling in asthma. Pharmacol Ther 2009; 122:19–29. doi:10.1016/j.pharmthera.2008.12.002.
   PubMed Web of Science ®Google Scholar
• Pepe C, Foley S, Shannon J, Lemiere C, Olivenstein R, Ernst P, Ludwig MS, et al. Differences in airway remodeling between subjects with severe and moderate asthma. J Allergy Clin Immunol 2005;116:544–549. doi:10.1016/j.jaci.2005.06.011.
   PubMed Web of Science ®Google Scholar
• Aysola RS, Hoffman EA, Gierada D, Wenzel S, Cook-Granroth J, Tarsi J, Zheng J, et al. Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology. Chest 2008;134:1183–1191. doi:10.1378/chest.07-2779.
   PubMed Web of Science ®Google Scholar
• Vrugt B, Wilson S, Bron A, Holgate St, Djukanovic R, Aalbers R. Bronchial angiogenesis in severe glucocorticoid-dependent asthma. Eur Respir J 2000;15:1014–1021. doi:10.1034/j.1399-3003.2000.01507.x.
   PubMed Web of Science ®Google Scholar
• Cohen L, E X, Tarsi J, Ramkumar T, Horiuchi TK, Cochran R, DeMartino S, et al. Epithelial cell proliferation contributes to airway remodeling in severe asthma. Am J Respir Crit Care Med 2007;176:138–145. doi:10.1164/rccm.200607-1062OC.
   PubMed Web of Science ®Google Scholar
• Weitoft M, Andersson C, Andersson-Sjöland A, Tufvesson E, Bjermer L, Erjefält J, Westergren-Thorsson G, et al. Controlled and uncontrolled asthma display distinct alveolar tissue matrix compositions. Respir Res 2014;15:67. doi:10.1186/1465-9921-15-67.
   PubMed Web of Science ®Google Scholar
• Ferreira DS, Carvalho-Pinto RM, Gregório MG, Annoni R, Teles AM, Buttignol M, Araújo-Paulino BB, et al. Airway pathology in severe asthma is related to airflow obstruction but not symptom control. Allergy 2018;73:635–643. doi:10.1111/all.13323.
   PubMed Web of Science ®Google Scholar
• Bazan-Socha S, Zuk J, Plutecka H, Marcinkiewicz C, Zareba L, Musial J. Collagen receptors α1β1 and α2β1 integrins are involved in transmigration of peripheral blood eosinophils, but not mononuclear cells through human microvascular endothelial cells monolayer. J Physiol Pharmacol 2012; 63:373–379.
   PubMed Web of Science ®Google Scholar
• Balzar S, Fajt ML, Comhair SAA, Erzurum SC, Bleecker E, Busse WW, Castro M, Et al. Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program. Am J Respir Crit Care Med 2011;183:299–309. doi:10.1164/rccm.201002-0295OC.
   PubMed Web of Science ®Google Scholar
• Andersson CK, Weitoft M, Rydell-Törmänen K, Bjermer L, Westergren-Thorsson G, Erjefält JS. Uncontrolled asthmatics have increased FceRI + and TGF-β-positive MCTC mast cells and collagen VI in the alveolar parenchyma. Clin Exp Allergy 2018;48:266–277.
   PubMed Web of Science ®Google Scholar
• Kupryś-Lipińska I, Molińska K, Kuna P. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma. Pneumonol Alergol Pol 2016;84:232–243. doi:10.5603/PiAP.2016.0029.
   PubMedGoogle Scholar
• Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanović R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000;161:9–16. doi:10.1164/ajrccm.161.1.9802048.
   PubMed Web of Science ®Google Scholar
• Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715–1721. doi:10.1016/S0140-6736(02)11679-5.
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029–1036. doi:10.1172/JCI17974.
   PubMed Web of Science ®Google Scholar